Issue 3 2017

18 LATIN AMERICA NEWS / Issue 3 2017 , GBT Acquires Laboratorio DOSA Grupo Biotoscana, a leading biopharmaceutical company in Latin America, has announced the acquisition of Laboratorio DOSA, a specialty pharmaceutical manufacturer based in Argentina. The transaction continues to advance GBT’s strategic agenda and expands GBT’s scope into the promising area of severe lung diseases. The bulk of DOSA’s products treat severe pulmonary pathologies. DOSA posted revenues of ARS326M (BRL61M) in 2016. The operation was closed at a price of USD29.9M. (approx. BRL 100M). GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/ rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world- class licenses and proprietary products. “Today’s announcement is an important milestone for us, as GBT continues to advance its strategic agenda and consolidates its position as the first pan-Latin American advanced medicines company,” said Mariano GarcíaValiño, Chief Executive Officer of the group. “The acquisition will enhance GBT’s product portfolio, add further in-house R&D and manufacturing capabilities, strengthen our product renewal pipeline and provide us with a new platform for growth and geographic expansion.” “The combination with GBT will help DOSA reach a number of key countries where the companies’ products have significant potential” said Carlos Estevez, Chief Executive Officer of DOSA. “We will also have the opportunity to introduce GBT and DOSA products to each other’s markets and customers.” Severe pulmonary diseases are one of the fastest- growing segment of the global pharmaceutical sector, according to a recent study by Allied Market Research. GBT will seek to capitalize on this significant opportunity by further expanding its regional footprint and diversifying its product portfolio through in-licensing and proprietary R&D.